Myeloid Derived Suppressor Cells: Subsets, Expansion, and Role in Cancer Progression by Jean-Pierre Abastado & Liang Zhi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Myeloid Derived Suppressor Cells: Subsets, 
Expansion, and Role in Cancer Progression 
Liang Zhi, Benjamin Toh and Jean-Pierre Abastado 
Singapore Immunology Network, BMSI, A-STAR 
Singapore 
1. Introduction 
Cancer immunotherapies have shown considerable promise in pre-clinical studies, but the 
potency of these interventions has often proved disappointing in vivo. This is in part due to 
tumor infiltration by myeloid cells, which are usually associated with less favorable clinical 
outcomes. In the past decade, several distinct subsets of tumor-infiltrating myeloid cells 
have been described (Movahedi et al., 2010), among which myeloid-derived suppressor cells 
(MDSC) have been subject to particular scrutiny for exerting a critical role in cancer 
progression (Bronte, 2009; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 
2009; Ribechini et al., 2010). MDSC have been studied intensively in the context of cancer, 
and the weight of evidence indicates that these cells accumulate in most human cancers and 
also in experimental animal models with transplanted or spontaneous tumors (Eruslanov et 
al., 2011; Gabitass et al., 2011; Movahedi et al., 2008; Peranzoni et al., 2010; Raychaudhuri et 
al., 2011; Youn et al., 2008). MDSC also have significant roles to play in numerous other 
pathologies, including bacterial infections (Delano et al., 2007), parasitic infections (Brys et 
al., 2005; Goni et al., 2002), chemotherapy outcomes (Angulo et al., 2000), experimental 
autoimmunity (Arora et al., 2011; Kerr et al., 2008; Moline-Velazquez et al., 2011; Zhu et al., 
2007), inflammatory bowel diseases (Haile et al., 2008), obesity (Xia et al., 2011), transplant 
rejection (Hock et al., 2011), and stress responses (Makarenkova et al., 2006). 
MDSC are a heterogeneous population of myeloid lineage cells that comprises progenitor 
cells, immature macrophages, immature granulocytes and immature dendritic cells 
(Gabrilovich and Nagaraj, 2009). MDSC lack specific phenotypic markers of macrophages, 
dendritic cells and monocytes, but instead exist as two morphologically distinct subsets: 
monocytic (MO)-MDSC and granulocytic/polymorphonuclear (PMN)-MDSC (Movahedi et 
al., 2008; Youn et al., 2008). MDSC populations accumulate and become activated in 
response to various factors released by tumor cells and/or by host cells in the tumor 
microenvironment, where they suppress both innate and adaptive anti-tumor immunity 
through a variety of different mechanisms. MDSC are therefore considered to be a major 
contributor to tumor immune evasion. However, the pro-tumor action of MDSC is not 
limited to their direct immunosuppressive properties - these cells have also been shown to 
favor cancer progression by promoting angiogenesis, cancer cell proliferation, invasion, and 
metastasis. The induction of MDSC by pro-inflammatory mediators and by tumor-derived 
soluble factors highlights key contributions from chronic inflammation and from the tumor 
microenvironment to the onset and progression of cancer.  
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In this chapter, we will review the recent literature on MDSC expansion, their role in cancer 
progression, their proposed mechanisms of action, and the therapeutic challenges of targeting 
MDSC. We will focus more specifically on mouse MDSC and their role in melanoma. 
2. Origin, distribution and expansion of MDSC 
Hematopoietic stem cells give rise to myeloid progenitor and precursor cells in bone 
marrow. Then these immature myeloid cells (IMC) migrate into peripheral lymphoid organs 
and differentiate into mature granulocytes, macrophages, or dendritic cells. Various sources 
of immunological stress, including cancer, inflammation, trauma, and autoimmune 
disorder, can inhibit the differentiation of IMC and thus promote the expansion of this 
population. IMC can subsequently become activated by tumor-derived factors and host 
cytokines which results in the generation of MDSC with potent immunosuppressive 
potential (Ribechini et al., 2010). In the steady state, IMC primarily reside in the bone 
marrow, but in pathological settings (cancer being the most well studied), MDSC can be 
detected in the bone marrow, spleen, blood, tumor, and also in lymph nodes (Haile et al., 
2008; Kusmartsev et al., 2005; Serafini et al., 2004; Sinha et al., 2008). 
The expansion, activation and accumulation of MDSC in peripheral tissues can be driven by 
multiple factors produced by tumor cells, tumor stromal cells, or by activated T cells. These 
mediators include prostaglandins; matrix metalloproteinases (MMPs); growth factors such 
as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), vascular 
endothelial growth factor (VEGF), stem-cell factor (SCF); cytokines such as transforming 
growth factor (TGF)-ǃ, tumor necrosis factor (TNF)-ǂ, interferon Ǆ (IFN-Ǆ), IL-1ǃ, IL-4, IL-6, 
IL-10, IL-12, IL-13; chemokines CCL2, CXCL5, CXCL12; and various other pro-inflammatory 
molecules including S100A8/9 proteins, toll-like receptor agonists, tumor-derived exosome-
associated Hsp72, inflammasome component NLRP3, and complement component C5a 
(Chalmin et al., 2010; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009; 
Ribechini et al., 2010; van Deventer et al., 2010). These agents either promote MDSC 
expansion through the JAK2/STAT3 signaling pathway or induce the activation of MDSC 
via STAT1, STAT6, or through NF-κB-dependent mechanisms (Gabrilovich and Nagaraj, 
2009; Kusmartsev and Gabrilovich, 2006).  
3. Subsets of murine MDSC  
MDSC comprise numerous different types of myeloid precursor cells. In mice, MDSC are 
characterized by the co-expression of surface markers Gr-1 and CD11b. In healthy mice, cells 
with this phenotype constitute around 20-30% of cells in bone marrow, approximately 2-4% of 
cells in the spleen, and fewer still in the lymph nodes (Kusmartsev and Gabrilovich, 2006), 
although the frequency of these cells can increase dramatically in tumor-bearing mice 
(Movahedi et al., 2008). Since Gr-1 antibodies can bind to two separate epitopes, Ly6G and 
Ly6C, it has recently become possible to further delineate MDSC subsets using antibodies that 
specifically target these distinct antigens. The Ly6G molecule is expressed primarily by 
granulocytes, whereas Ly6C is highly expressed by monocytes (Fleming et al., 1993; 
Sunderkotter et al., 2004). Among murine MDSC, the CD11b+Ly6G+Ly6Clow subset (PMN-
MDSC), exhibits a polymorphonulear phenotype, while the CD11b+Ly6G-Ly6Chigh subset 
(MO-MDSC), displays a monocytic phenotype. More recently, some new features of MDSC 
have emerged that provide further insights into the diversity of these cells. Using a simple 
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staining strategy, Greifenberg and colleagues were able to divide mouse splenocytes into six 
distinct sub-populations with regard to their size, granularity, morphology, and relative 
expression of CD11b and Gr-1 (Greifenberg et al., 2009). Among these various populations, Gr-
1lowCD11bhighLy6ChighSSClow and Gr-1highCD11blow (with ring-shaped nuclei) MDSC possessed 
suppressive potential. Additionally, Elkabets et al. identified a novel sub-population of murine 
MDSC that lacks Ly6C expression and predominates during IL-1ǃ-induced inflammatory 
responses. Ly6Cneg MDSC and Ly6Clow MDSC may constitute separate lineages of MDSC, or 
could perhaps represent distinct states of differentiation within a single MDSC lineage 
(Elkabets et al., 2010). In addition to Gr-1 and CD11b, several other surface molecules have 
been reported to discriminate between sub-populations of MDSC, including the co-stimulatory 
molecule CD80 (B7.1) (Yang et al., 2006), macrophage marker F4/80 (Huang et al., 2006), the 
M-CSF receptor (CSF1R/CD115) (Huang et al., 2006), and the ǂ-chain of the receptor for IL-4 
and IL-13 (IL-4Rǂ/CD124) (Gallina et al., 2006). MO-MDSC express higher levels of F4/80, 
CD115, 7/4, and CCR2 when compared with PMN-MDSC, which suggests a monocytic origin 
for these cells. However, further studies have demonstrated that, although these additional 
markers are undoubtedly expressed by MDSC, they do not specifically define a population of 
immunosuppressive cells (Youn et al., 2008). Indeed, while useful for analytical purposes, the 
Ly6G and Ly6C antibodies are not essential for identifying MDSC populations by flow-
cytometry: differential expression of Gr-1 and F4/80 alone can suffice to distinguish PMN-
MDSC (CD11b+Gr-1highF4/80-) from MO-MDSC (CD11b+Gr-1intF4/80int). The use of Ly6G-
specific antibodies is therefore only required when attempting to isolate a pure PMN-MDSC 
subset from a mixed cell population that also includes MO-MDSC (Toh et al., 2011). A 
summary of MDSC subsets can be found in Table 1.  
PMN-MDSC MO-MDSC
CD11b+Ly6G+Ly6Clow
CD11b+Ly6G-Ly6Chigh
Higher expression of F4/80, 
CCR2 and CD115
Cell contact-dependent
Antigen-specific 
immunosuppression
Cell contact-independent
Antigen-specific and antigen-
independent 
immunosuppression
Immune suppression via ROS-
mediated mechanisms
Immune suppression via 
arginase and NOS-mediated 
mechanisms
Terminally differentiated
Capable in differentiating into 
macrophages
 
Table 1. Main characteristics of two well-accepted MDSC subsets (Movahedi et al., 2008; 
Youn et al., 2008). It should be noted that some novel sub-populations of MDSC have 
recently been identified.  
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4. MDSC in cancer progression 
There is ample evidence from the literature that MDSC are associated with tumor progression. 
Adoptive transfer of MDSC in murine tumor models has been found to significantly promote 
tumor growth (Balwit et al., 2011; Yang et al., 2004), and administration of MDSC after 5-
Fluorouracil (5FU) injection blunted the anti-tumor effect of 5FU in tumor-bearing mice 
(Vincent et al., 2010). Depletion of Gr-1+ cells in tumor-bearing mice by injection of anti-Gr-1 
antibody strikingly inhibited tumor growth, reduced cancer cell dissemination and metastasis, 
and prolonged survival (Li et al., 2009; Pekarek et al., 1995; Zhang et al., 2009). Treatment of 
tumor-bearing mice with drugs that target MDSC, such as gemcitabine chemotherapeutic 
agent, all-trans-retinoic acid, and phosphodiesterase-5 inhibitors led to delayed tumor 
progression, improved survival, and enhanced efficacy of cancer vaccines and 
immunotherapies (Kusmartsev et al., 2003; Serafini et al., 2006; Suzuki et al., 2005). Reduction 
of murine MDSC numbers has also been shown to facilitate the rejection of established 
metastatic disease after the removal of primary tumors (Sinha et al., 2005). 
5. MDSC use multiple mechanisms to suppress T-cell function  
MDSC use a variety of different mechanisms to suppress anti-tumor immunity. Multiple 
lines of evidence indicate that MDSC are potent inhibitors of both antigen-specific and non-
specific T-cell activation.  
5.1 Arginase 
L-arginine is a conditionally essential amino acid and is primarily metabolized by arginases 
(ARGs) and nitric oxide synthases (NOSs) to produce either L-ornithine and urea, or to 
provide L-citrulline and nitric oxide (NO) (Bogdan, 2001; Morris, 2002; Wu and Morris, 
1998). The suppressive activity of MDSC was initially thought to be associated with the 
metabolism of L-arginine since depletion of this amino acid is accompanied by marked 
suppression of T-cell function and proliferation (Bronte et al., 2003; Bronte and Zanovello, 
2005; Rodriguez et al., 2005; Rodriguez and Ochoa, 2008). L-arginine deprivation has been 
reported to induce T-cell dysfunction via two distinct pathways, the first being loss of CD3ζ 
chain expression by these cells (Ezernitchi et al., 2006; Rodriguez et al., 2004; Rodriguez et 
al., 2002; Rodriguez et al., 2003a). CD3ζ is a key component of the T-cell receptor (TCR) and 
contains three immunoreceptor tyrosine-based activation motifs (ITAM) that generate an 
activation signal in T cells upon antigen recognition (Pitcher and van Oers, 2003). Lack of L-
arginine may therefore decrease the propensity for T cells to become activated by down-
regulating the CD3ζ signal transduction machinery. Alternatively, shortage of L-arginine 
may prevent the up-regulation of cell cycle regulators cyclin D3 and cyclin-dependent 
kinase 4 (CDK4) to arrest T cells in the G0-G1 phase of the cell cycle (Rodriguez et al., 2007). 
MDSC produce high levels of arginase, which depletes L-arginine in the local 
microenvironment, and can also uptake excess arginine through the CAT-2B transporter 
(Rodriguez et al., 2004; Rodriguez et al., 2003b). MDSC may therefore deprive T cells of L-
arginine to limit their proliferative potential, as well as decreasing TCR signaling, to induce 
broad suppression of T-cell function. These mechanisms seem to contribute to the pro-tumor 
function of MDSC, since injection of the arginase I inhibitor N-hydroxy-nor-l-arginine (Nor-
NOHA) in tandem with tumor implantation has been shown to significantly slow the 
growth of lung carcinoma in a dose-dependent manner. However, inhibition of tumor 
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growth upon Nor-NOHA treatment was not observed in tumor-laden SCID mice (severe 
combined immunodeficient animals), suggesting that the anti-tumor effect of arginase 
inhibition was dependent on lymphocyte function (Rodriguez et al., 2004). 
5.2 Nitric oxide 
L-arginine is a substrate for inducible nitric oxide synthase (iNOS) which is highly 
expressed in MDSC. Nitric oxide (NO) production via this pathway is a powerful modulator 
of inflammation and has been reported to preferentially inhibit Th1-mediated immune 
responses (Bauer et al., 1997; Sosroseno et al., 2009). NO potently suppresses T-cell 
activation, proliferation, adhesion, and migration (Bingisser et al., 1998; Bobe et al., 1999; 
Lejeune et al., 1994; Mazzoni et al., 2002; Medot-Pirenne et al., 1999; Sato et al., 2007). It 
suppresses T-cell function through blocking the activation of several important signaling 
molecules in T cells, including Janus-activated kinase 1 (JAK1), JAK3, signal transducer and 
activator of transcription 5 (STAT5), extracellular signal-regulated kinase (ERK), and AKT 
(Bingisser et al., 1998; Mazzoni et al., 2002). NO has also been shown to inhibit MHC class II 
expression and promote T-cell apoptosis (Harari and Liao, 2004; Rivoltini et al., 2002).  
5.3 Reactive oxygen species  
Reactive oxygen species (ROS) have emerged as a potential key mechanism of MDSC-induced 
immunosuppression in tumor-bearing hosts. Hyper-production of ROS is an archetypal 
feature of MDSC in both mouse tumor models and in human cancer patients (Greten et al., 
2011; Kusmartsev et al., 2004; Youn et al., 2008). Elevated ROS production by MDSC is 
mediated primarily by increased NADPH oxidase NOX2 activity (Corzo et al., 2009). In a 
previous report, lack of NOX2 activity abrogated the ability of MDSC to suppress T-cell 
responses (Corzo et al., 2009). Arginases and NOS can also contribute to the generation of ROS 
in MDSC: arginase depletion of L-arginine in the local environment triggers superoxide (O2–) 
generation from iNOS (Bronte et al., 2003; Xia et al., 1998). The unstable O2– anion can then 
react with protons in water to generate hydrogen peroxide. ROS appear then to exert a major 
role in MDSC-mediated T-cell suppression (Kusmartsev et al., 2008; Markiewski et al., 2008; 
Nagaraj et al., 2007) and have been implicated in the inhibition of antigen-specific CD8+ T-cell 
responses in tumor-bearing mice (Kusmartsev et al., 2004). ROS are also thought to play a 
direct role in inducing apoptosis of activated T cells by decreasing Bcl-2 expression (Hildeman 
et al., 2003). Accordingly, inhibition of ROS production in MDSC by the addition of ROS 
scavengers can reverse MDSC-mediated immune suppression and rescues IFN-Ǆ production 
(Kusmartsev et al., 2004; Kusmartsev et al., 2008).  
5.4 Peroxynitrite 
Peroxynitrite (ONOO-) is a reactive nitrogen-oxide species (RNOS) formed from the reaction 
between NO and O2– (Squadrito and Pryor, 1995). A major action of peroxynitrite is the 
modification of proteins by oxidation or nitration of the amino acids tyrosine, cystine, 
methionine, and tryptophan (Gabrilovich and Nagaraj, 2009). MDSC are copious producers 
of peroxynitrite, and increased levels of this species are associated with tumor progression 
(Cobbs et al., 2003; Ekmekcioglu et al., 2000; Nakamura et al., 2006). Hyper-production of 
peroxynitrite during direct contact with T cells allows MDSC to induce nitration of tyrosine 
residues in the TCR and CD8 co-receptor, leading to decreased conformational flexibility of 
the TCR chains and impaired interactions with MHC, thus inhibiting antigen-specific, 
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cytotoxic T-cell responses (Nagaraj et al., 2007). Peroxynitrite-driven nitration of tyrosine 
residues in human lymphocytes is also able to promote apoptotic cell death by inhibiting 
activation-induced tyrosine phosphorylation in these cells (Brito et al., 1999).  
5.5 Cysteine 
Recent work has demonstrated that murine MDSC block T-cell activation by depleting 
cysteine from the local microenvironment (Srivastava et al., 2010). Cysteine is an essential 
amino acid required for T-cell activation, differentiation and proliferation. Cells generate 
cysteine through two distinct pathways: the cystathionase enzyme can convert intracellular 
methionine into cysteine (Gout et al., 2001; Ishii et al., 2004), or alternatively, the plasma 
membrane cystine transporter xc− can import the oxidized form of the acid (cystine) from the 
extracellular environment. Imported cystine can then be reduced to form cysteine (Arner 
and Holmgren, 2000; Mansoor et al., 1992). Since T cells lack both cystathionase and an 
intact xc− transporter, they are unable to generate cysteine independently. Under 
homeostatic conditions, antigen-presenting cells (APC) provide cysteine to T cells by 
importing cystine, converting it to cysteine, and then exporting the cysteine through their 
plasma membrane ASC transporters (Sato et al., 1987; Angelini et al., 2002). Like T cells, 
MDSC lack cystathionase and depend on extracellular cystine for the synthesis of cysteine, 
but they lack the APC-expressed ASC transporter required to export cysteine. This results in 
MDSC readily importing cystine at a rate similar to that of macrophages and DC, but they 
do not export cysteine. This action depletes the environment of cysteine and results in the 
inhibition of T-cell activation and function (Srivastava et al., 2010).  
5.6 Alternative immunosuppressive mechanisms  
Alternative pathways have been identified through which MDSC might exert their 
suppressive functions. The immunoregulatory cytokine TGF-ǃ has been implicated in 
MDSC function. It is regulated in MDSC by IL-13 and CD4+ CD1d-restricted T cells. 
Blocking IL-13 or TGF-ǃ limited tumor incidence in murine transplanted tumor models 
(Fichtner-Feigl et al., 2008; Terabe et al., 2003). MDSC also have the ability to systemically 
down-regulate CD62L (L-selectin) on T cells in tumor-bearing mice. This action impairs 
naïve CD4+ and CD8+ T-cell homing to lymph nodes. Therefore, these T cells are not able to 
be activated by tumor antigens (Hanson et al., 2009). Down-regulation of CD62L was not 
due to general T-cell activation and could even be observed in tumor-free mice that 
exhibited high numbers of MDSC, (a common profile in aged animals). MDSC also 
constitutively express a disintegrin and metalloproteinase domain 17 (ADAM17, also 
known as TACE/TNFǂ-converting enzyme) on their cell surface, thus allowing the 
proteolytic cleavage and shedding of the ectodomain of CD62L (Hanson et al., 2009).  
Various reports have demonstrated that MDSC can induce the differentiation of regulatory 
T cells (Treg) in tumor-bearing hosts and indirectly promote immune suppression 
(Gabrilovich and Nagaraj, 2009). Treg induction can occur through diverse pathways that 
depend on the tumor model in use (Bianchi et al., 2011). In a mouse lymphoma model, 
induction of Treg is dependent on arginase and is independent of TGF-ǃ (Serafini et al., 
2008), but in murine ovarian cancer, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) 
expression on MDSC can mediate Treg induction (Yang et al., 2006). Another study by 
Huang et al. using several murine transplanted tumor models showed that IL-10 and IFN-Ǆ, 
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but not NO, were important factors in MDSC-mediated Treg development (Huang et al., 
2006). A more recent study has also reported that the immune stimulatory receptor CD40 on 
MDSC is required to induce tumor-specific Treg expansion in a mouse colon cancer model 
(Pan et al., 2010). 
5.7 Suppressive mechanisms differ between MDSC subsets 
In addition to morphological and phenotypic distinctions, PMN-MDSC and MO-MDSC also 
exert their suppressive activity by different mechanisms. MO-MDSC express high levels of 
NO and low levels of ROS, and they effectively suppress T-cell function in both antigen-
dependent and independent manners without requiring cell-cell contact. Primarily, MO-
MDSC inhibit T-cell function through NOS-mediated mechanisms since NOS inhibitors are 
able to block this suppressive effect. This pathway is IFN-Ǆ/STAT1-dependent (Movahedi et 
al., 2008; Youn et al., 2008). In contrast, PMN-MDSC produce high levels of ROS but only 
nominal amounts of NO, indicating that ROS are the primary mediators of their suppressive 
functions (Movahedi et al., 2008; Youn et al., 2008). PMN-MDSC generally require antigen-
specific interactions with T cells to mediate suppression (Nagaraj et al., 2007), although it 
has also been reported that PMN-MDSC do not require direct MHC I presentation to exert 
inhibitory effects (Movahedi et al., 2008). In most tumor models, PMN-MDSC are the main 
MDSC subset to be expanded in the peripheral lymphoid organs (Youn et al., 2008), while 
the MO-MDSC population possesses more potent inhibitory activity (Dolcetti et al., 2010; 
Movahedi et al., 2008; Nausch et al., 2008; Priceman et al., 2010). 
Murine splenic MDSC have also been shown to differ from their tumor-derived 
counterparts with regards to T-cell suppression. Tumor MDSC can potently suppress T-cell 
proliferation in both  antigen-specific and non-specific manner, whereas splenic MDSC are 
comparatively weak suppressor cells and exert only antigen-specific T-cell inhibition. This 
functional difference is suggested to be due to the different suppressive mechanisms used 
by splenic and tumor MDSC. Splenic MDSC suppress T cells through ROS production. In 
contrast, at the tumor site, MDSC, as a result of the effect of hypoxia via HIF-1ǂ, 
dramatically up-regulate inos and argI expression and therefore acquire the ability to inhibit 
antigen-nonspecific T-cell functions  (Corzo et al., 2010). 
6. Mechanisms by which MDSC disrupt innate immunity 
In addition to T-cell suppression, MDSC restrict innate responses via their interactions with 
macrophages, NK cells, and NKT cells to further impair anti-tumor immunity. Cross-talk 
between MDSC and macrophages results in increased MDSC production of the type 2 
cytokine IL-10, and decreased macrophage production of type 1 cytokine IL-12, which 
skews tumor immunity towards a tumor-promoting type 2 response (Sinha et al., 2007). 
The role of MDSC in regulating NK-cell function remains controversial. Some studies have 
shown that MDSC impair NK-cell development, IFN-Ǆ production and cytotoxicity against 
tumor cells. This suppression is mediated by membrane-bound TGF-ǃ1 and through down-
modulation of NKG2D (the primary activating receptor for NK cells) (Elkabets et al., 2010; 
Li et al., 2009; Liu et al., 2007; Suzuki et al., 2005). However, in a separate mouse study, MO-
MDSC isolated from RMA-S tumor-bearing mice failed to suppress NK-cell function, and 
instead elicited high production of IFN-Ǆ by these cells. These effects partially depended on 
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the interaction of NKG2D on NK cells with ligand RAE-1 on MDSC. Following activation, 
the NK cells eliminated the MDSC (Nausch et al., 2008). 
7. Non-immunosuppressive pro-tumor functions 
MDSC support for tumor growth does not depend solely on immunosuppression – these cells 
also promote tumor progression by augmenting blood vessel development and enhancing 
tumor-cell invasion and metastasis. In a murine colorectal cancer model (MC26), tumors co-
injected with MDSC from mice bearing large tumors exhibited increased vascular density and 
maturation, as well as decreased necrosis (Yang et al., 2004). Tumor growth was markedly 
facilitated when co-injected with tumor-derived MDSC, but not when co-injected with MDSC 
from normal mice. This increased vasculature was attributed to the production of MMP9, a 
critical mediator of tumor angiogenesis, vasculogenesis, and metastasis. MDSC-derived MMP9 
was shown to increase the bioavailability of VEGF in tumors and promote tumor angiogenesis 
and vascular stability. Accordingly, selective deletion of MMP9 in MDSC completely 
abolished their tumor-promoting activity (Yang et al., 2004). In a separate study using the 
mouse MT1A2 mammary cancer model, it was demonstrated that bone marrow-derived 
CD11b+ myelomonocytic cells significantly contributed to tumor vasculogenesis by producing 
MMP9 (Ahn and Brown, 2008). Various other MMPs, including MMP14, MMP13, and MMP2, 
were also found to be highly expressed in tumor-resident MDSC (Yang et al., 2008). These 
MDSC were recruited to the invasive front of mammary carcinomas with conditional deletion 
of the type II TGF-ǃ receptor gene. The MDSC infiltrate directly facilitated tumor invasion and 
metastasis through enhanced MMP and TGF-ǃ production (Yang et al., 2008). Furthermore, 
Bv8 protein (also known as prokineticin 2, or Prok2) has also been reported to contribute to 
MDSC-dependent tumor angiogenesis. Transplantation of tumor cells in mice resulted in 
significant up-regulation of Bv8 in MDSC, while treatment with neutralizing anti-Bv8 
antibodies suppressed tumor angiogenesis and inhibited tumor growth (Shojaei et al., 2007). In 
addition, murine tumor-associated MDSC were shown to confer tumor resistance to anti-
angiogenic therapy (anti-VEGF antibody) that was mediated by G-CSF and depended on Bv8 
expression. Combining anti-VEGF treatment with anti-Gr-1, anti-G-CSF, or anti-Bv8 antibody 
inhibited growth of refractory tumors more effectively that anti-VEGF therapy alone. Anti-G-
CSF treatment robustly reduced MDSC frequency in refractory tumors, decreased Bv8 levels, 
and inhibited tumor angiogenesis (Shojaei et al., 2009). The tumor microenvironment has also 
been proposed to support MDSC shape change and expression of endothelial markers such as 
VEGFR2 and VE-Cadherin (Yang et al., 2004), which may allow MDSC to differentiate locally 
and directly incorporate into the tumor endothelium to contribute to vascular development.  
Although MDSC up-regulation of proteases seems to be the primary route by which these 
cells promote tumor metastasis, a recent study by Boutte and colleagues also highlighted the 
importance of down-regulating protease inhibitors in tumor dissemination (Boutte et al., 
2011). In this study of transplanted tumors, neutrophilic granule protein (NGP: a cathepsin 
B inhibitor), was down-regulated in MDSC from metastatic tumor-bearing mice compared 
with non-metastatic controls. Up-regulation of NGP in tumors delayed primary tumor 
growth and greatly reduced tumor vasculature, invasiveness, and metastasis.  
MDSC have been further implicated in pre-metastatic niche formation in the lungs of tumor-
bearing mice. The concept of the pre-metastatic niche arises from the observation that many 
tumors have a pre-disposition to metastasize certain organs. Various leukocyte populations 
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and secreted inflammatory factors have been shown to “prepare” distal organs for 
metastatic cells (Hiratsuka et al., 2006; Kaplan et al., 2006; Kaplan et al., 2005), and MDSC 
can infiltrate the lungs of tumor-bearing mice before the arrival of tumor cells. These MDSC 
create a proliferative and immunosuppressive lung environment that is permissive for the 
growth of metastatic tumor cells. Pre-metastatic lungs with elevated MDSC have increased 
levels of basic fibroblast growth factor (bFGF), insulin growth factor 1 (IGF1), IL-4, IL-5, IL-
9, IL-10, and MMP9, whereas IFN-Ǆ is down-regulated in these lungs. Up-regulation of 
MMP9 in pulmonary MDSC drives abnormal vasculature development in the pre-metastatic 
lung (Yan et al., 2010), while myeloid cell-derived S100A8 and S100A9 pre-dispose the lung 
microenvironment towards eventual tumor metastasis (Hiratsuka et al., 2006). 
Finally, our own data reveal that PMN-MDSC promote melanoma cell proliferation by 
secreting soluble factors while also supporting cancer cell dissemination and metastasis by 
inducing epithelial-mesenchymal transition (Toh et al., 2011). These novel MDSC functions 
are discussed in more detail in the subsequent sections.  
8. Melanoma and the immune system 
Malignant melanoma is one of the most immunogenic forms of cancer and hundreds of 
immunotherapeutic trials have been conducted in melanoma patients to date. Substantial 
knowledge has been accumulated on the immunosuppressive pathways at work in 
melanoma and the role played by MDSC in disease progression. Tumor infiltrating 
lymphocytes (TIL) have been correlated with better prognoses and improved five-year 
survival rates (Day et al., 1981), and TIL isolated from melanoma patients are able to lyse 
MHC-matched allogeneic tumors (Degiovanni et al., 1988; Oble et al., 2009). However, the 
prognostic value of TIL is only valid in the early stages of melanoma, since TIL numbers in 
thick lesions do not predict clinical outcomes. Many melanoma-associated antigens are non-
mutated proteins that contribute to melanin synthesis, such as MelanA/MART-1, tyrosinase 
related protein (TRP)-1, TRP-2, gp100 and tyrosinase (Kawakami, 2000). Unfortunately, 
there has been only limited success in vaccinating patients with these antigens (Linette et al., 
2005). Large numbers of MelanA/MART-1 specific T cells have been found in the blood and 
tumors of melanoma patients (Salcedo et al., 2006), but only the circulating T cells were able 
to produce IFN-Ǆ and granzyme B upon antigen stimulation (Zippelius et al., 2004). These 
data indicate potent local immunosuppression at the tumor site which is most likely driven 
by immune cells recruited into the tumor itself. Accordingly, lymphocyte depletion has been 
shown to be effective method of enhancing adoptive T-cell transfer therapy in melanoma 
patients (Hershkovitz et al., 2010). In a clinical trial to test the efficacy of adoptive T-cell 
transfer in combination with lympho-depletion (non-myeloablative chemotherapy; NMC), 
better objective responses and complete remission could be achieved when NMC was 
combined with total body irradiation or high dose irradiation alone (Dudley et al., 2008). 
These findings suggest that tumor-induced immunosuppression does not arise from 
lymphocytes alone but also from myeloid cells. 
To study the complex interactions between tumors and the immune system, investigators 
are progressively turning to transgenic mice that develop spontaneous tumors and replicate 
human cancers more closely than transplanted tumor models. RETAAD mice are transgenic 
for the activated RET oncogene which is specifically expressed in melanocytes of the skin 
and eyes, leading to spontaneous skin tumors and primary uveal melanomas that are 
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clinically detectable by four to eight weeks of age. While exophthalmos eventually presents 
in adult RETAAD mice, microscopic eye tumors can be detected as early as ten days after 
birth, and cancer cells disseminate from the primary eye tumor throughout the body within 
three weeks (Eyles et al., 2010; Kato et al., 1998). Disseminated RETAAD cancer cells remain 
dormant for months before developing into cutaneous and visceral metastases, and the 
stepwise evolution of melanoma in these mice closely mimics the histopathology and 
natural history of human cancers (Eskelin et al., 2000; Kato et al., 1998; Kato et al., 2004). The 
RETAAD melanoma model is therefore particularly suitable for dissecting the role of host 
immune cells in metastatic processes.  
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Fig. 1. Immunosuppressive and non-immunosuppressive tumor-promoting functions of 
MDSC.         : Inhibition.          : Induction or promotion. 
Similar to human melanoma patients, tumors in RETAAD mice grow despite the induction 
of a broad melanoma-specific CD8+ T-cell response (Lengagne et al., 2008). It is surprising 
then that cutaneous tumor cell lines derived from RETAAD mice are still recognized by 
tumor-specific T cells, indicating that they are indeed antigenic (Lengagne et al., 2008). 
Functionally active, melanoma-specific, memory T lymphocytes can be detected at the early 
stages of melanoma progression, in the absence of clinically visible cutaneous tumors 
(Lengagne et al., 2008; Umansky et al., 2008). However, tumor progression continues despite 
the presence of these antigen-specific CD8+ T cells, suggesting that potent suppressive 
mechanisms shield the developing tumor from immune destruction. 
Even though a pathological role for Treg cells has been implicated in several tumor models, 
depletion of Treg in RET transgenic melanoma mice neither delayed nor inhibited tumor 
development (Kimpfler et al., 2009). In RET mice, intra-tumoral dendritic cell (DC) numbers 
correlated with tumor size, and DC from mice with macroscopic tumors secreted 
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significantly less IL-12p70, increased quantities of IL-10, and were impaired in their ability 
to activate T cells. The tolerogenic properties of these DC were mediated by IL-6, VEGF, and 
TGF-ǃ1 secreted in the tumor microenvironment (Zhao et al., 2009). Interestingly, in a 
separate study, IL-6 ablation in RET mice also reduced the incidence and size of tumors (von 
Felbert et al., 2005). Relative aggression of cutaneous tumors in RET mice correlated with 
numbers of tumor-infiltrating CD11b+Gr1low macrophages that displayed an M2-like, pro-
tumor phenotype, characterized by high transcript levels of il10, arginase I, mgl1, fizz1, and 
ccl2. Tumor- and spleen-derived macrophages in these mice were able to potently inhibit T-cell 
function. Surprisingly, depletion of T cells from RET mice resulted in the switching of these 
macrophages towards a M1, anti-tumor phenotype, characterized by secretion of IL-12. In the 
absence of T cells, macrophages in RET mice also displayed reduced ability to support tumor 
growth (Lengagne et al., 2011). In our own laboratory, we have further observed that the 
microenvironment of RETAAD cutaneous tumors supports only limited infiltration of CD4+ 
and CD8+ T cells compared with transplanted B16 tumors (Hong et al., 2011). 
9. MDSC in melanoma 
We have observed that CD11b+Gr1high PMN-MDSC are increased in the spleen and blood of 
RETAAD mice during tumor progression. PMN-MDSC, but not MO-MDSC, preferentially 
accumulate in the primary tumor compared with metastases, which is due to the expression 
of CXCL1, CXCL2 and CXCL5 (chemotactic mediators specific for PMN-MDSC) in the 
primary tumor, but not in metastases. PMN-MDSC notably affect two primary aspects of 
tumor progression – tumor growth and metastasis. In RETAAD mice, depletion of PMN-
MDSC by treatment with anti-Ly6G antibody resulted in a decrease in primary tumor size, 
but failed to diminish cutaneous tumors (which have low infiltrates of PMN-MDSC). 
Furthermore, early depletion of PMN-MDSC (before primary tumor development) resulted 
in decreased proliferation of primary tumors, while in vitro assays demonstrated that the 
ability to induce cancer cell proliferation is specific to PMN-MDSC but not macrophages. 
These data also indicate that PMN-MDSC are able to directly induce tumor cell proliferation 
by secreting a soluble factor (Toh et al., 2011). 
PMN-MDSC also induce epithelial-mesenchymal transition (EMT) which is the first step 
towards metastasis in early stage cancers (Toh et al., 2011). Depletion of PMN-MDSC 
reduced dissemination of tumor cells to distant metastatic sites such as the lungs and the 
tumor-draining lymph nodes. Primary tumor cells in control mice exhibited higher 
expression of mesenchymal markers S100A4 and vimentin compared with mice depleted of 
PMN-MDSC. In vitro, PMN-MDSC were also able to down-modulate E-Cadherin, a classical 
epithelial marker, in both mouse and human melanoma cells. Induction of EMT was 
dependent on TGF-ǃ, epidermal growth factor and hepatocyte growth factor, since blockade 
of these molecules either individually or in combination resulted in partial or complete 
inhibition of EMT (Toh et al., 2011). 
The ability of melanomas to evade immune destruction depends on components of the host 
immune system. While extensive research has already been conducted on immunotherapy 
strategies that enhance T-cell responses against tumors, improving the efficacy of these 
interventions will require a better understanding of the interactions between melanoma cells 
and the immune system, with a particular focus on immunosuppressive MDSC populations. 
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Additional research will also be required to determine whether MDSC are capable of 
inducing cancer cell proliferation and epithelial-mesenchymal transition in other types of 
cancers besides melanoma.  
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Fig. 2. Roles of MDSC in the growth, invasion, and metastasis of melanoma. 
10. Therapeutic strategies targeting MDSC 
Recognition that MDSC-mediated immune suppression plays a pivotal role in tumor 
progression highlights these cells as an appealing target for novel cancer treatments. Agents 
that modulate MDSC development, differentiation and recruitment, or block the 
suppressive functions of these cells could represent potent new methods of limiting tumor 
progression, or could perhaps enhance the efficacy of existing therapies. Limiting the 
infiltration and activation of MDSC during chronic inflammation may even reduce the risk 
of de novo tumor development.  
10.1 Promoting MDSC differentiation 
Given the fact that MDSC are immature myeloid cells, a promising approach in cancer 
immunotherapy would be to drive MDSC differentiation into mature populations that no 
longer have suppressive activity. Vitamin A has been identified as a candidate agent that 
possesses this ability, since vitamin A deficiency causes systemic expansion of MDSC in 
mice (Kuwata et al., 2000). Vitamin A metabolites such as retinoic acid have been found to 
favor MDSC differentiation into mature DC, macrophages, and granulocytes. Treatment of 
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mouse or human MDSC with all-trans-retinoic acid (ATRA) in vitro resulted in induction of 
myeloid cell differentiation (Almand et al., 2001; Gabrilovich et al., 2001; Hengesbach and 
Hoag, 2004; Kusmartsev et al., 2008). Using adoptive transfer of MDSC into congenic mice, 
Kusmartsev et al. were able to demonstrate that ATRA also induced rapid differentiation of 
MDSC into mature myeloid cells in vivo (Kusmartsev et al., 2003). In tumor-bearing mice, 
ATRA administration substantially reduced the presence of MDSC and noticeably improved 
CD4+ and CD8+ T-cell-mediated anti-tumor immune responses. Combination of ATRA with 
two different types of cancer vaccines significantly prolonged the anti-tumor effect of the 
vaccination in two different mouse tumor models (Kusmartsev et al., 2003). Moreover, in 
human patients with metastatic renal cell carcinoma, effective concentrations of ATRA were 
shown to eliminate MDSC and improve antigen-specific T-cell responses (Kusmartsev et al., 
2008; Mirza et al., 2006). Vitamin D derivatives have also been reported to drive myeloid 
progenitor cell differentiation both in vitro and in vivo (Duits et al., 1992; Testa et al., 1993). 
25-hydroxyvitamin D3 treatment in patients with head and neck squamous cell carcinoma 
diminished the number of immuno-suppressive CD34+ progenitor cells and improved 
numerous parameters of immune responsiveness (Lathers et al., 2004).  
10.2 Inhibiting MDSC expansion 
As described above, many tumor-derived factors can induce the development and 
expansion of MDSC from hematopoietic precursors (see also section 2). Neutralization of 
these mediators is therefore another attractive strategy for novel cancer therapies. For 
example, stem-cell factor (SCF) has been identified as a vital mediator of MDSC expansion 
and accumulation, since SCF knockdown using silencing RNA decreased MDSC frequency 
and reversed tumor-specific T-cell tolerance in the mouse MCA26 colon cancer model. 
Blocking SCF interactions with its receptor, c-kit, by the use of specific antibodies 
dramatically reduced the MDSC population and prevented tumor-specific T-cell anergy, 
Treg development, and tumor angiogenesis, resulting in tumor regression and enhanced 
efficacy of immune-activating cancer therapy (Pan et al., 2008). Another study also reported 
that melanoma development is restrained in RET-transgenic mice with impaired c-kit 
function, or when RET mice are treated with anti-c-kit antibody. Although the authors 
attributed this phenomenon to the direct function of c-kit in tumor cells, we cannot exclude 
the possibility that the suppression of tumor development was due to attenuated MDSC 
expansion caused by c-kit impairment (Kato et al., 2004). 
MMP9 inhibition is another logical therapeutic approach in cancer therapy due to the MDSC 
requirement for MMP9 in supporting their expansion and function. In a spontaneous mouse 
mammary tumor model, treatment with a MMP9 inhibitor (amino-biphosphonate) was 
shown to significantly reduce MDSC expansion and impair tumor growth, while 
simultaneously enhancing tumor necrosis and improving the anti-tumor responses induced 
by immunotherapy (Melani et al., 2007). Finally, targeting the intracellular signaling 
pathways that are involved in MDSC expansion is also a promising strategy. Using selective 
STAT3 inhibitors, such as JSI-124 (cucurbitacin I), or tyrosine kinase inhibitors, such as 
sunitinib, can augment anti-tumor immune responses by reducing the presence of MDSC. 
Sunitinib combination therapy with IL-12 and 4-1BB activation significantly improved the 
long-term survival rate of mice bearing MCA26 colon tumors (Ko et al., 2009; Nefedova et 
al., 2005; Ozao-Choy et al., 2009). In a more recent study, treating mice with docetaxel anti-
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mitotic, chemotherapeutic reagent was found to polarize MDSC towards a M1-like 
phenotype by inhibiting STAT3 activation, and consequently restored CD4+ and CD8+ T-cell 
function to reduce 4T1-Neu tumor burden (Kodumudi et al., 2010).  
10.3 Eliminating MDSC 
Direct elimination of MDSC can be achieved with chemotherapeutic drugs such as 
gemcitabine, which dramatically and specifically reduces MDSC numbers in tumor-bearing 
mice, but spares CD4+ T cells, CD8+ T cells, NK cells, macrophages, and B cells. This 
beneficial loss of MDSC is also accompanied by an increase in the anti-tumor activity of the 
preserved CD8+ T-cell and NK-cell pool (Suzuki et al., 2005). Treatment with 5-fluorouracil 
(5FU) has also been shown to induce selective apoptosis of MDSC, thereby decreasing the 
burden of these cells in murine spleen and tumor beds, but without depleting host T cells, 
NK cells, dendritic cells, or B cells. The elimination of MDSC by 5FU treatment also 
increased IFN-Ǆ production by tumor-specific CD8+ T cells and promoted T-cell–dependent 
anti-tumor responses (Apetoh et al., 2011; Vincent et al., 2010).  
10.4 Blocking MDSC suppressive function 
Another approach to restricting MDSC support for tumor progression is to block the 
immunosuppressive function of these cells. Since ARG1 and NOS2 are the primary 
mediators of MDSC immunosuppression, these enzymes are the most likely targets for 
novel therapeutic interventions. Various different drugs including nitro-aspirin, COX-2 
inhibitors, and phosphodiesterase-5 (PDE5) inhibitors have been shown to profoundly 
inhibit both ARG1 and NOS2 activity in MDSC. By removing MDSC suppressive mediators, 
these drugs exhibited a potent ability to restore anti-tumor immune responses and delayed 
tumor progression in several mouse models (De Santo et al., 2005; Serafini et al., 2006; 
Talmadge et al., 2007; Zea et al., 2005). Interestingly, in addition to inhibiting MDSC 
function, COX2 inhibitors also blocked the systemic development of MDSC as well as CCL2-
mediated accumulation of these cells in the tumor microenvironment in a mouse model of 
glioma (Fujita et al., 2011). 
11. Conclusion 
In recent years, it is becoming increasingly apparent that the immuno-suppressive 
mechanisms operating in cancer patients significantly contribute to tumor progression and 
attenuate the efficacy of immunotherapies. The tumor microenvironment incorporates 
several distinct immunosuppressive cell populations that play dominant roles in this 
process. MDSC are a heterogeneous population of immature myeloid cells that possess 
potent ability to inhibit immune responses. These MDSC also have the capacity to promote 
angiogenesis, cancer cell proliferation, and epithelial-mesenchymal transition, and thus 
enhance cancer growth, invasion, and metastasis. Controlling the expansion and 
accumulation of MDSC or blocking their suppressive functions represents promising novel 
approaches in cancer therapy. However, vital questions remain to be answered if this 
potential is to be fully realized. What is the predominant mechanism driving the 
differentiation and activation of MDSC? Which mechanisms primarily contribute to the 
suppressive activities of MDSC? What are the dynamics of MDSC migration into tumor 
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tissues and peripheral lymphatic organs, and which factors affect their trafficking? Do 
different subsets of MDSC differ in their function, and does this difference depend on the 
cancer sub-type? Are there better specific markers that would allow investigators to identify 
functional MDSC and distinguish various subpopulations of MDSC (particularly in 
humans)? Solving these questions will advance our understanding of the critical role of 
MDSC in cancer and could aid the development of novel interventions for cancer treatment.  
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